Discussions around diversity, equity, and inclusion (DEI) in clinical trials have become increasingly central in drug development. Despite this evolution, there remain gaps in understanding about where accessibility fits within DEI strategies and initiatives.

These gaps present a significant challenge to research in general, but particularly in rare diseases where patient populations are much smaller and margins for error narrow. With these constraints in mind, inclusive trial design is essential, and accessibility can often become a critical success factor.

 In this series, attendees will learn about:

  • Myriad types of accessibility considerations for rare disease clinical research
  • How accessibility considerations fit into DEI plans
  • Best practices in accessible clinical trial design and implementation

Each panel, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.


Read more about our speakers.

Accessibility Considerations

The following accessibility considerations have been provided for each panel event.

Live event

- Live ASL translation

- Closed captioning will be provided (English)



All registered attendees will be emailed a link to:

- Video recordings

- Subtitled video recording and full transcripts in:

- Spanish

- Mandarin

- French

- Portuguese

- Hindi

- German

All translation services provided courtesy of ICON Language Services.